Related Experiment Videos
Phenobarbital: does the positive result in TA1535 indicate genotoxic properties?
1Pharma Division, F. Hoffmann-La Roche Ltd; Basel, Switzerland.
Environmental and Molecular Mutagenesis
|January 1, 1992
Summary
Phenobarbital (PB), a liver carcinogen, weakly increases mutations in the Ames test. It enhances mutations caused by other agents, suggesting indirect DNA damage modulation rather than direct genotoxicity.
Area of Science:
- Toxicology
- Genetics
- Carcinogenesis
Background:
- Phenobarbital (PB) is a known liver carcinogen.
- PB shows a weak increase in mutant frequency in the Ames test (strain TA1535) without metabolic activation (S9).
- The mechanism behind PB's effect is unclear, lacking direct DNA reactivity.
Purpose of the Study:
- To investigate indirect mechanisms of PB's mutagenic effects.
- To explore synergistic and comutagenic properties of PB.
- To compare PB's effects with other carcinogens like methapyrilene.
Main Methods:
- Ames test using various bacterial strains (TA1535 and others).
- Combination assays with PB and known mutagens (Na-azide, 2-aminoanthracene, 4-nitroquinoline N-oxide, 2-nitrofluorene).
- Evaluation of mutant frequency and synergistic/comutagenic effects.
Main Results:
- PB exhibited strong synergistic and comutagenic effects with Na-azide and 2-aminoanthracene across all tester strains.
- PB did not enhance the mutagenicity of 4-nitroquinoline N-oxide or 2-nitrofluorene.
- Methapyrilene, another non-genotoxic carcinogen, displayed similar properties to PB.
Conclusions:
- PB's effect in the Ames test is likely due to modulation of spontaneous DNA lesion fixation and expression, not direct genotoxicity.
- PB acts indirectly, enhancing the mutagenic potential of specific agents.
- These findings suggest a non-genotoxic mechanism for PB and similar carcinogens.